| Literature DB >> 32855206 |
Yongsheng Li1, Brandon Burgman1,2, Daniel J McGrail3, Ming Sun4, Dan Qi5, Sachet A Shukla6, Erxi Wu1,5,7, Anna Capasso1,2, Shiaw-Yih Lin4, Catherine J Wu6, S Gail Eckhardt1,2, Gordon B Mills8,9, Bo Li10, Nidhi Sahni11,12,13, S Stephen Yi14,2,15,16.
Abstract
Alterations in immune-related pathways are common hallmarks of cancer. A comprehensive understanding of how cancer mutations rewire immune signaling networks and functional output across cancer types is instrumental to realize the full potential of immunotherapy. Here, we systematically interrogated somatic mutations involved in immune signaling that alter immune responses in patients with cancer. To do so, we developed a Network-based Integrative model to Prioritize Potential immune respondER genes (NIPPER). Identified mutations were enriched in essential protein domains and genes identified by NIPPER were associated with responsiveness to multiple immunotherapy modalities. These genes were used to devise an interactome network propagation framework integrated with drug-associated gene signatures to identify potential immunomodulatory drug candidates. Together, our systems-level analysis results help interpret the heterogeneous immune responses among patients and serve as a resource for future functional studies and targeted therapeutics. SIGNIFICANCE: This study demonstrates that integration of multi-omics data can help identify critical molecular determinants for effective targeted therapeutics. ©2020 American Association for Cancer Research.Entities:
Mesh:
Year: 2020 PMID: 32855206 PMCID: PMC7642109 DOI: 10.1158/0008-5472.CAN-20-0384
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 12.701